EMIF Deliverable 3.2: 4 Proteomic based plasma markers for prognosis

Executive summary

Executive Summary

The aim of this deliverable is to carry out both untargeted discovery of novel plasma protein biomarkers and targeted replication studies of previously identified plasma protein biomarkers of AD prognosis (including MCI conversion to AD and rates of cognitive decline).

All proteomic data has been acquired and processed for both the untargeted proteomics (somascan based discovery) and targeted immunocapture based proteomics (MSD, luminex xMAP and ELISA). A data analysis plan has been compiled and agreed by the WP3 working group, and a data dictionary including all outcome variables and covariates to be considered by the group is being assembled.

Analysis of all plasma proteomic data acquired to date will be complete within the next two months. The plasma proteomic data will then be included in further multimodal analysis, incorporating the other modality data acquired in this study (plasma metabolomics, CSF proteomics, genomics and structural MRI).

Contacts

EMIF-AD: Alison Baird and Simon Lovestone
alison.baird@psych.ox.ac.uk / simon.lovestone@psych.ox.ac.uk